Skip to main
  1. Stocks
  2. Globus Medical
  3. Forecast
GMED

Globus Medical (GMED) Stock Forecast & Price Target

Globus Medical (GMED) Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 31%
Buy 46%
Hold 23%
Sell 0%
Strong Sell 0%

Bulls say

Globus Medical is positioned well for above-market growth because Q1'26 showed broad-based demand, with $760MM revenue up 11.2% organic, EPS of $1.12 versus $0.92 consensus, and strong gains in U.S. Spine, trauma, and Enabling Technologies. The company’s outlook is supported by durable execution and margin expansion, as gross margin reached 69.2%, adjusted EBITDA margin was 32.3%, and management raised 2026 EPS guidance to $4.70-$4.80 while reaffirming $3.18-$3.22B in sales. Its longer-term case is strengthened by a debt-free balance sheet with $799MM cash, 30+ new product launches since fiscal 2022 close, and a robotics-led ecosystem that is driving share gains, recurring revenue opportunities, and international expansion.

Bears say

Globus Medical is facing a negative fundamental setup because its downside case depends on slower adoption of ExcelsiusGPS robotics and Excelsius3D Imaging, weaker pull-through to implants, and delayed recon robotics, all of which could constrain growth in its higher-value enabling technologies. The bear case also points to revenue growth slowing to the low-single digits with flat margins, while inflation, supply disruptions, staffing shortages, and pricing pressure threaten its industry-leading mid-70s gross margins and mid-30s operating margins. Competitive pressure from larger medtech players such as MDT, SYK, and ZBH, plus merger-related execution risk from GMED/Nuvasive, could further disrupt spine share and undermine earnings quality.

Globus Medical (GMED) has been analyzed by 13 analysts, with a consensus rating of Buy. 31% of analysts recommend a Strong Buy, 46% recommend Buy, 23% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Globus Medical and is not a guaranteed prediction by Public.com or investment advice.

Globus Medical (GMED) Analyst Forecast & Price Prediction

Get the latest Globus Medical (GMED) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Globus Medical (GMED)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Globus Medical (GMED) Forecast

Analysts have given Globus Medical (GMED) a Buy based on their latest research and market trends.

According to 13 analysts, Globus Medical (GMED) has a Buy consensus rating as of Oct 30, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $97.69, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $97.69, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Globus Medical (GMED)


Globus Medical (GMED) Analyst Forecast & Price Prediction

Get the latest Globus Medical (GMED) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Globus Medical (GMED)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover GMED stock data and trends